Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477338 | 0.93 | ELANE (0.62) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL21892004 | 0.84 | KDM4E (0.55) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL18285081 | 0.83 | ELANE (1.00) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL21892018 | 0.82 | ALDH1A1 (0.58) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL31211469 | 0.82 | CYP2C19 (0.80) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL5048036 | 0.82 | CYP2C19 (0.80) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL29690272 | 0.82 | CYP2C19 (0.80) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL5048033 | 0.82 | CYP2C19 (0.80) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL29583383 | 0.82 | CYP2C19 (0.80) | ELANEMAPTKDM4EGAAXBP1 | |
| SCHEMBL18106013 | 0.81 | ALDH1A1 (0.59) | MAPTKDM4EGAAXBP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015070226-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | ELANE 1672/4885MAPT 4171/4885KDM4E 90/4885 |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | ELANE 1672/4885MAPT 4171/4885KDM4E 90/4885 |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | ELANE 1672/4885MAPT 4171/4885KDM4E 90/4885 |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | ELANE 1672/4885MAPT 4171/4885KDM4E 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.